vs

Side-by-side financial comparison of FENNEC PHARMACEUTICALS INC. (FENC) and Ispire Technology Inc. (ISPR). Click either name above to swap in a different company.

Ispire Technology Inc. is the larger business by last-quarter revenue ($20.3M vs $13.8M, roughly 1.5× FENNEC PHARMACEUTICALS INC.). Ispire Technology Inc. runs the higher net margin — -32.5% vs -34.7%, a 2.2% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs -51.5%). Over the past eight quarters, Ispire Technology Inc.'s revenue compounded faster (-17.8% CAGR vs -26.3%).

Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.

Ispire Technology Inc. is a global tech firm specializing in R&D, manufacturing and sales of advanced vaporization hardware and supporting consumables. It serves nicotine and legal cannabis consumer markets, operates two core segments of hardware and branded cannabis products, covers North America, Europe and Asia-Pacific, delivering compliant innovative vapor solutions for B2B partners and end users.

FENC vs ISPR — Head-to-Head

Bigger by revenue
ISPR
ISPR
1.5× larger
ISPR
$20.3M
$13.8M
FENC
Growing faster (revenue YoY)
FENC
FENC
+125.3% gap
FENC
73.8%
-51.5%
ISPR
Higher net margin
ISPR
ISPR
2.2% more per $
ISPR
-32.5%
-34.7%
FENC
Faster 2-yr revenue CAGR
ISPR
ISPR
Annualised
ISPR
-17.8%
-26.3%
FENC

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
FENC
FENC
ISPR
ISPR
Revenue
$13.8M
$20.3M
Net Profit
$-4.8M
$-6.6M
Gross Margin
17.1%
Operating Margin
-18.5%
-33.9%
Net Margin
-34.7%
-32.5%
Revenue YoY
73.8%
-51.5%
Net Profit YoY
-141.1%
17.4%
EPS (diluted)
$-0.17
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FENC
FENC
ISPR
ISPR
Q4 25
$13.8M
$20.3M
Q3 25
$12.5M
$30.4M
Q2 25
$9.7M
$20.1M
Q1 25
$8.8M
$26.2M
Q4 24
$7.9M
$41.8M
Q3 24
$7.0M
$39.3M
Q2 24
$7.3M
$37.3M
Q1 24
$25.4M
$30.0M
Net Profit
FENC
FENC
ISPR
ISPR
Q4 25
$-4.8M
$-6.6M
Q3 25
$-638.0K
$-3.3M
Q2 25
$-3.2M
$-14.8M
Q1 25
$-1.2M
$-10.9M
Q4 24
$-2.0M
$-8.0M
Q3 24
$-5.7M
$-5.6M
Q2 24
$-5.6M
$-3.5M
Q1 24
$12.8M
$-5.9M
Gross Margin
FENC
FENC
ISPR
ISPR
Q4 25
17.1%
Q3 25
17.0%
Q2 25
12.3%
Q1 25
18.2%
Q4 24
18.5%
Q3 24
19.5%
Q2 24
28.3%
Q1 24
20.4%
Operating Margin
FENC
FENC
ISPR
ISPR
Q4 25
-18.5%
-33.9%
Q3 25
-1.5%
-8.9%
Q2 25
-28.3%
-72.7%
Q1 25
-9.2%
-40.4%
Q4 24
-11.8%
-17.6%
Q3 24
-74.6%
-13.4%
Q2 24
-69.4%
-9.2%
Q1 24
54.2%
-18.8%
Net Margin
FENC
FENC
ISPR
ISPR
Q4 25
-34.7%
-32.5%
Q3 25
-5.1%
-10.7%
Q2 25
-32.7%
-73.4%
Q1 25
-13.3%
-41.5%
Q4 24
-25.0%
-19.1%
Q3 24
-82.2%
-14.2%
Q2 24
-76.5%
-9.4%
Q1 24
50.6%
-19.7%
EPS (diluted)
FENC
FENC
ISPR
ISPR
Q4 25
$-0.17
$-0.12
Q3 25
$-0.02
$-0.06
Q2 25
$-0.11
$-0.26
Q1 25
$-0.04
$-0.19
Q4 24
$-0.02
$-0.14
Q3 24
$-0.21
$-0.10
Q2 24
$-0.20
$-0.07
Q1 24
$0.41
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FENC
FENC
ISPR
ISPR
Cash + ST InvestmentsLiquidity on hand
$36.8M
$17.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$35.5M
$-7.7M
Total Assets
$70.6M
$84.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FENC
FENC
ISPR
ISPR
Q4 25
$36.8M
$17.6M
Q3 25
$21.9M
$22.7M
Q2 25
$18.7M
$24.4M
Q1 25
$22.7M
$23.5M
Q4 24
$26.6M
$34.4M
Q3 24
$40.3M
$37.7M
Q2 24
$43.1M
$35.1M
Q1 24
$51.2M
$39.5M
Total Debt
FENC
FENC
ISPR
ISPR
Q4 25
Q3 25
$19.4M
Q2 25
$19.4M
Q1 25
$19.4M
Q4 24
$19.3M
Q3 24
$32.1M
Q2 24
$31.8M
Q1 24
$31.3M
Stockholders' Equity
FENC
FENC
ISPR
ISPR
Q4 25
$35.5M
$-7.7M
Q3 25
$-4.5M
$-1.8M
Q2 25
$-7.5M
$604.7K
Q1 25
$-5.9M
$14.8M
Q4 24
$-5.9M
$24.2M
Q3 24
$-5.2M
$30.7M
Q2 24
$-1.4M
$34.5M
Q1 24
$3.0M
$35.9M
Total Assets
FENC
FENC
ISPR
ISPR
Q4 25
$70.6M
$84.4M
Q3 25
$49.3M
$96.4M
Q2 25
$44.9M
$102.2M
Q1 25
$46.4M
$115.7M
Q4 24
$44.9M
$132.0M
Q3 24
$58.9M
$129.0M
Q2 24
$63.2M
$122.6M
Q1 24
$69.2M
$108.0M
Debt / Equity
FENC
FENC
ISPR
ISPR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
10.40×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FENC
FENC
ISPR
ISPR
Operating Cash FlowLast quarter
$-6.0M
$-4.0M
Free Cash FlowOCF − Capex
$-4.0M
FCF MarginFCF / Revenue
-19.9%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-14.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FENC
FENC
ISPR
ISPR
Q4 25
$-6.0M
$-4.0M
Q3 25
$1.5M
$-1.2M
Q2 25
$-3.7M
$4.7M
Q1 25
$-4.3M
$-12.5M
Q4 24
$-1.5M
$-3.2M
Q3 24
$-2.2M
$3.6M
Q2 24
$-8.4M
$-1.4M
Q1 24
$39.0M
$3.4M
Free Cash Flow
FENC
FENC
ISPR
ISPR
Q4 25
$-4.0M
Q3 25
$-1.2M
Q2 25
$3.7M
Q1 25
$-12.7M
Q4 24
$-3.2M
Q3 24
$3.3M
Q2 24
$-2.2M
Q1 24
$3.3M
FCF Margin
FENC
FENC
ISPR
ISPR
Q4 25
-19.9%
Q3 25
-3.9%
Q2 25
18.6%
Q1 25
-48.4%
Q4 24
-7.7%
Q3 24
8.5%
Q2 24
-5.9%
Q1 24
10.9%
Capex Intensity
FENC
FENC
ISPR
ISPR
Q4 25
0.3%
Q3 25
0.0%
Q2 25
4.8%
Q1 25
0.7%
Q4 24
0.1%
Q3 24
0.7%
Q2 24
2.0%
Q1 24
0.3%
Cash Conversion
FENC
FENC
ISPR
ISPR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
3.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons